
Dominick J. Angiolillo MD, PhD
Professor of Medicine; Director, Cardiovascular Research; Program Director, Interventional Cardiology Fellowship, University of Florida College of Medicine-Jacksonville, Jacksonville, FloridaDisclosures
1. Receive(d) Payment as an Individual for Consulting Fee or Honorarium from: Bristol-Myers Squibb, Sanofi-Aventis, Eli Lilly, Daiichi Sankyo, The Medicines Company, AstraZeneca, Merck, Evolva, Abbott Vascular, Bayer and PLx Pharma
2. Receive(d) Payment as an Individual for Participation in Review Activities from: Johnson & Johnson, St. Jude, and Sunovion
3. Received Institutional Payments for Grants from: Bristol-Myers Squibb, Sanofi-Aventis, GlaxoSmithKline, Otsuka, Eli Lilly, Daiichi Sankyo, The Medicines Company, AstraZeneca, and Evolva
Recent Contributions to PracticeUpdate:
- Early Intervention Is Optimal in NSTE-ACS Without Pretreatment
- Aspirin Desensitization in Patients With CAD
- MY APPROACH to Choosing an ADP Inhibitor in Acute Coronary Syndrome
- Morphine Associated With a Delayed Activity of Oral Antiplatelet Agents in Patients With STEMI Undergoing Primary PCI
- MY APPROACH to Dual Antiplatelet Therapy After Elective PCI
- Optimal Platelet Inhibition in Non–ST-Elevation ACS